TY - JOUR
T1 - Catharanthine alkaloids are noncompetitive antagonists of muscle-type nicotinic acetylcholine receptors
AU - Arias, Hugo R.
AU - Feuerbach, Dominik
AU - Targowska-Duda, Katarzyna M.
AU - Jozwiak, Krzysztof
N1 - Funding Information:
This research was supported by grants from the Science Foundation Arizona and Stardust Foundation and the Office of Research and Sponsored Programs , Midwestern University (to H.R.A.), by the Polish Ministry of Science and Higher Education (No. N405 297036 ) and by the FOCUS and TEAM research subsidy from the Foundation for Polish Science (to K.J.). The authors thank to the National Institute on Drug Addiction (NIDA, NIH, Bethesda, MD, USA) for the gift of [ 3 H]Ibogaine, ibogaine, and phencyclidine. The authors also thank to Dr. James Trudell (Stanford University, CA, USA) for his useful comments on the manuscript, and to Jorgelina L. Arias Castillo and Paulina Iacoban for their technical assistance.
PY - 2010/9/1
Y1 - 2010/9/1
N2 - We compared the interaction of several catharanthine alkaloids including, ibogaine, vincristine, and vinblastine, with that for the noncompetitive antagonist phencyclidine (PCP) at muscle nicotinic acetylcholine receptors (AChRs) in different conformational states. The results established that catharanthine alkaloids: (a) inhibit, in a noncompetitive manner, (±)-epibatidine-induced Ca2+ influx in TE671-hα1β1γδ cells with similar potencies (IC50=17-25μM), (b) inhibit [3H]TCP binding to the desensitized Torpedo AChR with higher affinity compared to the resting AChR, and (c) enhance [3H]cytisine binding to resting but activatable Torpedo AChRs, suggesting desensitizing properties. Interestingly, PCP inhibits [3H]ibogaine binding to the AChR in a steric fashion. This is corroborated by additional docking experiments indicating that the amino groups of neutral ibogaine form hydrogen bonds with the serine ring (position 6'), a location shared with PCP. Since protonated ibogaine forms a salt bridge with one of the acidic residues at the outer ring (position 20'), this ligand could be first attracted to the entrance of the channel by electrostatic interactions. Our data indicate that the catharanthine moiety is a minimum structural requirement for AChR inhibition including, ion channel blocking and desensitization, and that ibogaine and PCP bind to overlapping sites in the desensitized AChR ion channel.
AB - We compared the interaction of several catharanthine alkaloids including, ibogaine, vincristine, and vinblastine, with that for the noncompetitive antagonist phencyclidine (PCP) at muscle nicotinic acetylcholine receptors (AChRs) in different conformational states. The results established that catharanthine alkaloids: (a) inhibit, in a noncompetitive manner, (±)-epibatidine-induced Ca2+ influx in TE671-hα1β1γδ cells with similar potencies (IC50=17-25μM), (b) inhibit [3H]TCP binding to the desensitized Torpedo AChR with higher affinity compared to the resting AChR, and (c) enhance [3H]cytisine binding to resting but activatable Torpedo AChRs, suggesting desensitizing properties. Interestingly, PCP inhibits [3H]ibogaine binding to the AChR in a steric fashion. This is corroborated by additional docking experiments indicating that the amino groups of neutral ibogaine form hydrogen bonds with the serine ring (position 6'), a location shared with PCP. Since protonated ibogaine forms a salt bridge with one of the acidic residues at the outer ring (position 20'), this ligand could be first attracted to the entrance of the channel by electrostatic interactions. Our data indicate that the catharanthine moiety is a minimum structural requirement for AChR inhibition including, ion channel blocking and desensitization, and that ibogaine and PCP bind to overlapping sites in the desensitized AChR ion channel.
KW - Ca influx
KW - Catharanthine alkaloids
KW - Ibogaine
KW - Molecular modeling
KW - Nicotinic acetylcholine receptors
KW - Noncompetitive antagonists
KW - Nonformational states
KW - Vinca alkaloids
UR - http://www.scopus.com/inward/record.url?scp=77953911700&partnerID=8YFLogxK
U2 - 10.1016/j.neuint.2010.05.007
DO - 10.1016/j.neuint.2010.05.007
M3 - Article
C2 - 20493225
AN - SCOPUS:77953911700
SN - 0197-0186
VL - 57
SP - 153
EP - 161
JO - Neurochemistry International
JF - Neurochemistry International
IS - 2
ER -